Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
The Global BioAccess Fund, based in New York, specializes in the biopharmaceutical sector. Founded to partner with companies developing transformative technologies, it manages investments ranging from $1 million to $10 million. The firm has a portfolio of nine companies and focuses on addressing significant health challenges.
This fund invests in early-stage companies creating novel therapeutics and devices in Oncology, Immunology and Inflammation, cardiovascular diseases, CNS disorders, and rare diseases. Targeting Series A to Series C rounds, Global BioAccess Fund supports innovations that tackle unmet medical needs with substantial financial backing.
Notable portfolio companies include Epsilogen, which develops IgE antibodies for cancer treatment; VITTORIA Biotherapeutics, focusing on CD5 for cell therapies; and Cartography Biosciences, pioneering cancer antigen mapping. Other investments include Acesion Pharma, SHIRATRONICS, Ensho Therapeutics, Odyssey Therapeutics, Nuvig Therapeutics, and Alveus Therapeutics.
Email your pitch deck to info@globalbioaccess.com for consideration.
Yes, the fund often leads investment rounds, particularly in Series A to C stages.
The firm is open to follow-on investments, providing additional capital as companies progress through their development stages.
The fund has the capacity to invest up to $10 million throughout a company's lifespan, although the total fund size is not specified.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.